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Introduction
Myotonic dystrophy type I (DM1; OMIM #160900) is a multisys-
temic neuromuscular disorder, which represents the most common 
form of muscular dystrophy in adults (1). In particular, DM1 patients 
suffer from muscle wasting, weakness, and myotonia. DM1 is an 
autosomal dominant disease caused by an expansion of unstable 
CTG repeats located within the 3′-UTR of the dystrophia myotonica 
protein kinase (DMPK) gene. Toxic expanded transcripts contain-
ing RNA hairpins formed by the triplet repeats accumulate as RNA 
foci in the nuclei of affected cells (2, 3). These mutant transcripts are 
thought to sequester RNA-binding proteins, such as muscleblind-like 
1 (MBNL1), and to increase CUG triplet repeat RNA-binding protein 
1 (CUGBP1) levels. The resulting splicing defects are considered the 
primary cause of DM1 symptoms (4–6). HSALR mice, which carry 
a CTG repeat expansion in the human skeletal actin (HSA) gene, 
constitute a well-characterized mouse model for DM1 (5). These 
mice express (CUG)n-expanded transcripts specifically in skeletal 
muscle and reiterate the dystrophic phenotype and myotonic dis-
charges observed in muscle of patients. HSALR mice also recapitulate 
DM1 molecular characteristics such as foci accumulation, MBNL1 
sequestration, and splicing abnormalities (5, 7, 8). Therapeutic strat-
egies have mainly focused on targeting DM1-associated mis-splicing 
and mRNA toxicity (9–11), although a more complete understanding 
of pathogenic pathways would clearly be of interest for the develop-
ment of alternative or additional therapeutic options.
Recently, deregulation of cellular processes and signaling 
pathways important for maintaining proper muscle homeostasis 
has been reported in DM1. This includes abnormal activation of 
the ubiquitin-proteasome system and increased autophagic flux, 
which were both related to muscle atrophy and weakness in DM1 
(12–14). In parallel, perturbation in the PKB/Akt pathway may arise 
from altered expression of the insulin receptor, which correlates 
with glucose intolerance in DM1 patients (15). Although PKB/Akt 
deregulation has been reported in Dmpk-deficient mice (16), in 
DM1 flies (13), and in DM1 human neural stem cells (17), contra-
dictory results have been obtained in human muscle cells (18, 19).
To obtain further insight into the pathomechanisms associ-
ated with the disease, we investigated whether deregulated met-
abolic pathways may be involved in muscle alterations in DM1. 
We uncovered that muscles from HSALR mice do not efficiently 
respond to fasting by displaying impaired activation of AMPK and 
delayed inhibition of the mTOR complex 1 (mTORC1) pathway. 
Moreover, we observed mild perturbations of the autophagic flux 
in both HSALR muscle and myotubes from DM1 patients, which 
may arise from AMPK/mTORC1 deregulation. Importantly, we 
established that treatments normalizing these pathways improved 
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in muscle from 2-month-old mice analyzed in fed conditions or 
subjected to a physiological stimulus like fasting (20). No major 
difference was observed in the activation state of AMPK, PKB/Akt, 
and mTORC1 pathways in muscle from fed mutant and control 
mice, as reflected by the similar phosphorylation levels of AMPK 
(AMPKP172), PKB/Akt (AktP473), and the mTORC1 targets ribosomal 
protein S6 kinase (p70S6KP389) and S6 ribosomal protein (S6P235/6 
and S6P240/4) (Figure 1, A and B). After 24 hours of starvation, 
HSALR mice showed impaired activation of the AMPK pathway, 
as revealed by the reduced levels of AMPKP172 in tibialis anteri-
or (TA) mutant muscle (Figure 1A). Regardless of the nutritional 
status, protein expression of the known AMPK regulatory kinases 
skeletal muscle strength and strongly reduced the myotonia in 
HSALR mice. Our data provide evidence for the pathological role of 
metabolic pathways in DM1 and may open interesting avenues for 
alternative therapeutic strategies for the disease.
Results
AMPK and mTORC1 pathways are deregulated in HSALR muscle. To 
identify pathomechanisms involved in DM1-related muscle alter-
ations, we examined the potential deregulation of metabolic path-
ways in HSALR mice (Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI89616DS1). 
To this purpose, the activation state of key proteins was compared 
Figure 1. AMPK and mTORC1 pathways do not respond to starvation in HSALR muscle. (A and B) Two-month-old HSALR and control (Ctrl) mice were exam-
ined in fed conditions and after 24 hours of starvation (St24). Immunoblots for phospho- (P) and total proteins of the AMPK (A) and mTORC1 (B) pathways 
reveal reduced AMPK activation and increased phosphorylation of some mTORC1 targets upon starvation in mutant muscle. Samples were run on the same 
gel but were noncontiguous. Protein quantification is given for AMPKP172 (n = 4 Ctrl and 3 HSALR), CaMKIIβM, AktP473, mTORP2448 (Fed, n = 3; St24, n = 4), and 
S6P235/6 (Fed, n = 3; St24, n = 7 Ctrl and 6 HSALR). Data are relative to fed control mice and are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA 
with Tukey’s multiple comparisons test correction. (C) Immunostaining on muscle cross sections from fed and starved (St24) HSALR and control (Ctrl) mice 
shows high levels of phospho-S6 in mutant muscle upon starvation. Scale bar: 100 μm.
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from muscles with a constant activation (TSCmKO; ref. 27) or deple-
tion (RAmKO; ref. 28) of mTORC1 (Supplemental Figure 1D). Nota-
bly, no major change in the phosphorylation of mTOR was observed 
in mutant and control muscles from fed versus starved mice (Fig-
ure 1B). Moreover, upon starvation, changes in 4E-BP1 levels were 
similar between HSALR and control muscles (Figure 1B), consistent 
with previous reports indicating differential regulation of mTORC1 
targets (29). Interestingly, mTORC1 deregulation was not related to 
abnormal activity of PKB/Akt, since levels of the active phosphory-
lated form of PKB/Akt were efficiently decreased upon starvation in 
mutant mice (Figure 1B). Accordingly, we did not detect any changes 
in the splicing (exon 11, mis-spliced in DM1 patients) or expression of 
the gene encoding insulin receptor (Insr) in TA muscle from 2-month-
old HSALR mice (Supplemental Figure 1E). Moreover, mTORC1 and 
AMPK activation state in nonmuscle tissue, such as liver, was similar 
in control and mutant mice (Supplemental Figure 1F), indicating that 
deregulation of these pathways is confined to skeletal muscles, which 
specifically express (CUG)n-expanded transcripts.
In an attempt to normalize mTORC1/AMPK pathways, con-
trol and HSALR mice were subjected to starvation for 45 hours. 
Mutant mice lost less weight than controls after prolonged star-
vation (Supplemental Figure 2). Moreover, upon 45 hours of star-
liver kinase B1 (LKB1) and TGF-β–activated kinase 1 (TAK1) was 
unchanged in HSALR muscle compared with control (Figure 1A). 
In contrast, mutant muscle displayed an altered expression pro-
file for Ca2+-calmodulin–dependent kinase II (CaMKII) isoforms, 
with marked reduction in levels of the CaMKIIβM muscle-specif-
ic form and of its phosphorylated, active form (Figure 1A). Such 
deregulation was consistent with splicing defects in the Camk2 
genes previously described in tissues from DM1 patients and 
mouse models (11, 21–23). We confirmed by quantitative PCR that 
splicing of Camk2b was altered in muscle from HSALR mice (exon 
13 exclusion; Supplemental Figure 1B), while overall expression 
of Camk2 transcripts was unchanged in comparison with controls 
(Supplemental Figure 1C). As CaMKII regulates AMPK (24–26), 
these results suggest that impaired AMPK activation in HSALR 
muscle may rely on mis-splicing–dependent CaMKII deficiency.
In parallel, higher phosphorylation of p70S6K and S6 was detect-
ed upon starvation in HSALR muscle compared with control muscle 
(Figure 1B). Accumulation of phosphorylated S6 in muscle from 
starved mutant mice was further confirmed by immunostaining (Fig-
ure 1C), suggesting an abnormal activation of the mTORC1 signaling 
in HSALR mice. The specificity of the staining was confirmed by use 
of the S6P235/6 blocking peptide and by immunostaining of sections 
Figure 2. AMPK and mTORC1 pathways can 
be modulated by caloric and pharmacolog-
ical treatments in HSALR muscle. Immuno-
blots for phospho- (P) and total AMPK and S6 
proteins reveal efficient inhibition of mTORC1 
signaling upon 45 hours of starvation (St45, 
A) and with metformin (MetF, B) or rapamy-
cin (Rapa, C) treatment in muscle from HSALR 
mice. AMPK activation shows a trend toward 
increase in mutant muscle with metformin 
treatment (B). Samples were run on the same 
gel but were noncontiguous. Protein quan-
tification is shown for AMPKP172 and S6P235/6 
(Fed, n = 3; St45, n = 4 Ctrl and 3 HSALR; Veh 
[B], n = 3; MetF, n = 4; Veh [C], n = 4 Ctrl and 
3 HSALR; Rapa, n = 3 per genotype). Data are 
relative to fed (A) or vehicle-treated (B and C) 
control mice and are mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001, 2-way ANOVA with 
Tukey’s multiple comparisons test correction.
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and does not involve ERK/p90S6K, which can also phosphorylate 
S6 at Ser235/6 (30). Levels of AMPKP172 remained unchanged in 
rapamycin-treated mice (Figure 2C). Although no obvious change 
was detected in AMPK-dependent phosphorylation of TSC2 
(TSC2P1387), an upstream inhibitor of mTORC1 (Figure 1B), these 
results suggest that AMPK deregulation may primarily be respon-
sible for the defective response to starvation and for mTORC1 sig-
naling perturbation in HSALR muscle.
Autophagic flux is perturbed in HSALR muscle. It is well established 
that mTORC1 and AMPK are key regulators of autophagy and that 
perturbation of their activities can lead to severe tissue alterations, 
especially in skeletal muscle (31–33). To determine whether the 
expression of the CUG repeats impairs the autophagy process, we 
vation, 4E-BP1 and phospho-S6 levels were similar in mutant 
and control muscles, while AMPK phosphorylation showed only 
a trend toward increase in HSALR muscle (Figure 2A). We next 
addressed whether pharmacological treatments would be suf-
ficient to modulate AMPK/mTORC1 pathways in HSALR mice. 
Control and mutant mice were treated for 5 days with metformin, 
a drug known to induce AMPK signaling. The treatment slightly 
activated AMPK in muscle from starved HSALR mice, which was 
accompanied by a decrease in phospho-S6 levels (Figure 2B). 
Conversely, a single injection of rapamycin, a canonical inhibi-
tor of mTORC1, strongly reduced S6P235/6 levels in muscle from 
HSALR mice, to levels similar to those in controls. This further con-
firmed that S6 deregulation is dependent on mTORC1/p70S6K 
Figure 3. HSALR muscles show mild deregulation of the autophagic flux. (A) Immunoblots for autophagy-related proteins show accumulation of auto-
phagic substrates in HSALR TA muscle in fed conditions. A reduced LC3I-to-LC3II switch is observed in mutant muscle upon 24 hours of starvation (St24), 
compared with control (Ctrl). Samples were run on the same gel but were noncontiguous. (Fed, n = 3; St24, n = 7 Ctrl and 6 HSALR for LC3 ratio, n = 4 for 
p62.) For LC3I and LC3II levels, see Supplemental Figure 3A. (B) HSALR mice expressing GFP-LC3 display increased number of GFP-positive puncta in TA 
muscle compared with control (Ctrl) in fed conditions (n = 3 Ctrl and 4 HSALR), but reduced accumulation after 24 hours of starvation (St24, n = 3). Scale 
bar: 50 μm; 10 μm for insets. A volume unit (vol) corresponds to 2.8 × 103 μm3. (C) Treatment with colchicine (Colch) leads to milder changes in LC3II levels 
in TA muscle from fed and starved HSALR mice, compared with control (Ctrl) mice. For LC3II/LC3I quantification, see Supplemental Figure 3C. (D) Immuno-
staining of muscle sections from starved control (Ctrl) and HSALR mice reveals no major accumulation of p62 or ubiquitinated proteins in mutant muscle. 
Scale bar: 100 μm. Data are relative to control fed mice and represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA with 
Tukey’s multiple comparisons test correction.
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due to increased autophagy induction in HSALR muscle; accumu-
lation of autophagic vesicles was therefore likely related to restrict-
ed degradation. Consistently, levels of the autophagosome cargo 
protein p62 were higher in muscle from fed mutant mice than in 
controls (Figure 3A). However, we detected neither p62 aggregates 
nor accumulation of ubiquitinated proteins in muscle from fed 
and starved HSALR mice (Figure 3D), indicating that autophagy is 
only mildly affected. Similarly, distribution of lysosomal vesicles, 
visualized by LAMP1 immunostaining, was unchanged between 
2-month-old mutant and control mice (Supplemental Figure 3D). 
Together, these results suggest that autophagy is slightly deregulat-
ed in DM1 muscle, which results from reduced degradation in com-
bination with attenuated autophagy induction upon starvation.
Under fed conditions, increased amounts of p62 and LC3II 
were not due to abnormal transcript expression in HSALR muscle 
(Figure 4A). Moreover, expression of the Map1lc3b, Sqstm (encod-
ing p62), and Ctsl (encoding cathepsin L) genes was unchanged 
after 24 hours of fasting, but we observed an efficient induction 
of the genes upon 45 hours of starvation in both mutant and con-
trol muscles (Figure 4A and Supplemental Figure 4A). It should be 
noted that following prolonged starvation, autophagy induction 
remained weaker in mutant muscle compared with control muscle 
(Figure 4B and Supplemental Figure 4B). To gain further insight 
into autophagy deregulation, we assessed the phosphorylation 
state of Unc-51–like kinase 1 (ULK1), as mTORC1 and AMPK phos-
phorylate and thereby inhibit or activate ULK1, respectively (31). 
Upon starvation, levels of the inactive form of ULK1 (ULK1P757) 
remained slightly higher in mutant muscle as compared with con-
trol muscle, while no major difference was observed for its active 
form (ULK1P317; Figure 4C and Supplemental Figure 4C). Interest-
ingly, rapamycin and metformin treatments were both sufficient 
assessed the ability of HSALR muscle to induce autophagy when the 
mice were subjected to starvation. First, we evaluated levels of the 
soluble (LC3I) and autophagosome-associated (LC3II) forms of the 
widely used LC3B (MAP1LC3 for microtubule-associated protein 
light chain 3) autophagy marker. The amount of LC3II correlates with 
the intracellular accumulation of autophagic vesicles (34). Under fed 
conditions, LC3II levels were increased, although not significantly, 
in mutant muscle, which reflects either a slight increase in autophagy 
induction or a mild defect in the degradation steps (Figure 3A and 
Supplemental Figure 3A). After 24 hours of starvation, a clear switch 
from LC3I to LC3II occurred in control muscle, while HSALR muscle 
displayed reduced changes in LC3 levels and LC3II/LC3I ratio (Fig-
ure 3A and Supplemental Figure 3A). To confirm these results, we 
starved HSALR and control mice expressing the GFP-LC3 fusion pro-
tein for 24 hours. In control muscle, a striking increase in the number 
of GFP-LC3–positive puncta, representing autophagic vesicles, was 
observed upon starvation (Figure 3B and Supplemental Figure 3B). 
In HSALR mice, the number of puncta was higher under fed condi-
tions, but was significantly less increased upon starvation as com-
pared with control muscle (Figure 3B and Supplemental Figure 3B). 
These results confirmed that autophagy is perturbed in HSALR mus-
cle, which may rely on impaired induction and/or degradation steps.
To assess the status of the autophagic flux, mice were treat-
ed for 2 days with colchicine, a drug preventing degradation of 
the autophagic content. Under both fed and starved conditions, 
colchicine induced a major switch from LC3I to LC3II in control 
muscle (Figure 3C). Comparing colchicine-treated and untreated 
mice, we observed that the fold change in the LC3II/LC3I ratio 
was less in HSALR muscle compared with controls, in both fed and 
starved conditions (Figure 3C and Supplemental Figure 3C). This 
result ruled out that elevated LC3II levels in fed conditions were 
Figure 4. HSALR muscles display perturbed response of autophagy to caloric and pharmacological treatments. (A) Expression of autophagy-related genes 
is efficiently upregulated after 45 hours of starvation (St45) in HSALR TA muscle. Data are normalized to Actn2 levels (Fed, n = 4; St45, n = 4 Ctrl and 3 
HSALR). Data are relative to control fed mice and represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA with Tukey’s multiple compar-
isons test correction. (B) Immunoblots reveal limited switch from LC3I to LC3II in HSALR muscle upon 45 hours of starvation (St45) compared with controls 
(Ctrl). Samples were run on the same gel but were noncontiguous. For LC3II/LC3I quantification, see Supplemental Figure 4B. (C) Levels of the inhibited 
phosphorylated form of ULK1 (SerP757) remain slightly higher upon starvation in HSALR muscle, compared with control (Ctrl) muscle. For quantification, see 
Supplemental Figure 4C. (D and E) Immunoblots for LC3 show blunted induction of LC3II upon rapamycin (Rapa, D) or metformin (MetF, E) treatments, com-
pared with controls (Ctrl). For LC3II/LC3I quantification, see Supplemental Figure 4, D and E. Samples were run on the same gel but were noncontiguous.
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to increase LC3II levels in control muscle, but did not induce 
autophagy in HSALR muscle (Figure 4, D and E, and Supplemental 
Figure 4, D and E). Hence, mTORC1/AMPK deregulation in con-
junction with mTORC1/AMPK–independent mechanisms likely 
contributes to autophagy perturbation in HSALR muscle.
Lastly, upon starvation, expression of the atrogenes Trim63 
and Fbxo32 was similarly induced in HSALR and control muscles 
(Supplemental Figure 4F). However, caspase- and trypsin-like 
activities associated with the proteasome system were increased 
in muscle from fed and starved mutant mice, compared with con-
trol animals (Supplemental Figure 4G). This is consistent with a 
previous report showing higher proteasome activity in muscle 
from a DM1 mouse model expressing 550 CTG triplets (12).
Involvement of AMPK/mTORC1 deregulation in DM1 pathology. 
To ascertain the relevance of the changes observed in HSALR mice 
for DM1 pathology, we evaluated the activation state of AMPK/
Figure 5. Autophagy perturbation contributes to muscle alterations in DM1. (A) Protein lysates from muscle biopsies of control individuals (C1–5) and 
DM1 patients (P1–3) were analyzed for phospho- (P) and total proteins of the AMPK and PKB/Akt–mTORC1 pathways. (B) MyoD-transduced fibroblasts 
from controls (Ctrl) and DM1 patients were differentiated to myotubes and subjected to growth medium (GM) or deprived conditions (PBS) for 3 hours. 
Immunoblots for phospho- (P) and total proteins reveal increased phospho-S6 levels upon deprivation in the 3 cell lines of DM1 patients (DM-L1–3), com-
pared with controls. Samples were run on the same gel but were noncontiguous. Quantification is given for deprived conditions; values are mean ± SEM 
of technical replicates. (C) Immunoblots for LC3 marker show defective accumulation of LC3II in DM1 myotubes upon energy and amino acid deprivation 
(PBS) as well as with deprived conditions and chloroquine treatment (Chloro), compared with control cells (Ctrl). Quantification of LC3II/LC3I ratio is shown 
for 2 DM1 cell lines (DM-L1/2) in enriched (GM) and deprived conditions; values are mean ± SEM of technical replicates. (D) H&E stain reveals the presence 
of vacuolated fibers (arrows) in muscle biopsy from 1 DM1 patient, together with lysosomal accumulation (arrowheads) observed by immunostaining in 
some affected muscle fibers (red, bottom panel). Scale bars: 50 μm. (E) Vacuoles (arrows) are observed in muscle from aging HSALR mice; the periphery of 
the vacuoles is strongly reactive with anti-LAMP1 antibodies (red, bottom panel), indicating accumulation of lysosomal structures in these regions. High 
density of lysosomes is also observed in nonvacuolated muscle fibers from 12-month-old (12M) mutant mice (arrowheads), compared with muscle from 
age-matched control mice (Ctrl). Scale bars: 50 μm.
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI89616
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 5 5jci.org   Volume 127   Number 2   February 2017
mTORC1 signaling in muscle biopsies from 3 DM1 patients (P1–3) 
of 33, 34, and 49 years of age. There was no major difference in 
total and phosphorylated levels of PKB/Akt and AMPK proteins 
in muscle from DM1 patients compared with age-matched control 
individuals (C1/2 and C3–5 aged 30 and 50 years, respectively) 
(Figure 5A). Notwithstanding, we noticed that levels of the active 
phosphorylated forms of p70S6K and S6 were increased in mus-
cle biopsies from DM1 patients compared with control individuals 
(Figure 5A). However, the nutritive status of the patients at the time 
of the biopsy could not be ascertained and may have influenced the 
results. For this reason, we next tested the ability of DM1 human 
muscle cells to modulate mTORC1/AMPK signaling in response 
to energy and nutrient deprivation. Fibroblasts of 3 DM1 patients 
(DM-L1–3) were transduced with MyoD and differentiated for 10 
days into myotubes, before being subjected to growth medium 
or to amino acid– and glucose-deprived conditions (i.e., PBS) for 
3 hours. Upon deprivation, levels of the active phosphorylated 
forms of PKB/Akt and S6 were strongly reduced in control muscle 
cells; there was no major activation of AMPK in comparison with 
enriched conditions (Figure 5B). A similar response was observed 
in DM1 muscle cells, although they retained higher phosphoryla-
tion of S6 in deprived conditions compared with control cells (Fig-
ure 5B). In parallel, a major switch from LC3I to LC3II occurred in 
control muscle cells upon deprivation. LC3II levels were further 
increased in control cells treated with chloroquine, consistent with 
high autophagy induction in deprived cells (Figure 5C). In contrast, 
LC3II levels were only slightly changed when DM1 myotubes were 
subjected to deprivation, even in the presence of chloroquine, indi-
cating that the autophagic flux is blocked at the induction steps 
(Figure 5C). Together, these data indicate that DM1 human muscle 
cells do not efficiently respond to nutrient/energy deprivation and 
display deregulation of the autophagy process.
Figure 6. AICAR markedly decreases myotonia in HSALR mice and reduces mis-splicing in mutant muscle. (A) In vitro tetanic stimulation of EDL muscle 
reveals strongly increased relaxation time in HSALR muscle. (B) Metformin (MetF) treatment does not reduce muscle late relaxation time in 4-month-old 
(Ctrl, n = 5; HSALR, n = 6 Veh and 8 MetF) and 12-month-old (Ctrl, n = 3; HSALR, n = 7 Veh and 8 MetF) HSALR mice, as compared with vehicle-treated mutant 
mice. (C) Inclusion of exon 7a of the Clcn1 gene is not changed in muscle from metformin-treated (MetF) HSALR mice, compared with vehicle-treated mice 
(n = 3). (D) Immunoblots for phospho- and total S6 protein reveal efficient inhibition of indirect AMPK target in muscle from control (Ctrl) and mutant 
mice treated with AICAR. Samples were run on the same gel but were noncontiguous. (E) AICAR treatment normalizes the time to relax of HSALR muscle 
upon tetanic stimulation, compared with muscle from vehicle-treated (Veh) mutant mice. (F) Late relaxation time is significantly reduced in EDL muscle 
from 2-month-old (n = 3 Ctrl and 4 HSALR), 8-month-old (Ctrl, n = 3; HSALR, n = 6 Veh and 7 AICAR), and 12-month-old (n = 4 Veh and 5 AICAR) HSALR mice 
that were treated with AICAR, as compared with age-matched vehicle-treated (Veh) mutant mice. (G–K) End-point PCR (G) and quantitative PCR (H and I) 
reveal strong reduction in exon 7a inclusion of the Clcn1 gene in muscle from HSALR mice treated with AICAR, compared with vehicle-treated (Veh) mutant 
mice (Ctrl, n = 3; HSALR, n = 5 Veh and 4 AICAR [G], n = 5 [I]). Protein levels of CLC-1 are also increased in mutant muscle from AICAR-treated mice (J and K, 
n = 3 Ctrl and 4 HSALR). (L) Quantitative PCR shows similar transcript levels of Rbm3 in muscle from AICAR-treated and untreated mice (n = 3 Ctrl and 4 
HSALR). Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA with Tukey’s multiple comparisons test correction 
(except 12M AICAR, unpaired 2-tailed Student’s t test).
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the vacuoles, and we did not observe such fea-
tures in muscle from age-matched control mice 
(Figure 5E and Supplemental Figure 5B). Electron 
microscopy confirmed the presence of vacuoles in 
mutant mouse muscle: they were surrounded by 
dense, disorganized areas of contractile elements 
and usually limited by a single, discontinuous 
membrane (Supplemental Figure 5C). Together 
with the lysosome staining, these features argue 
for the presence of autophagic vacuoles in muscle 
from older HSALR mice. These results suggest that 
autophagy perturbation may contribute to the 
alteration of muscle tissue in DM1, but is unlikely 
to be a predominant feature of the disease.
AICAR, an AMPK agonist, abrogates myoto-
nia in HSALR mice. In light of the deregulation of 
AMPK signaling in HSALR muscle, we investigated 
whether AMPK normalization would have a ben-
eficial effect on muscle function in mutant mice. 
As readout of the disease, we evaluated myotonia 
by measuring the late relaxation time of skeletal 
muscle (i.e., time to reduce the maximal force 
from 50% to 10%) after ex vivo tetanic stimula-
tion (8). As reported previously, we observed no 
change in the late relaxation time of soleus muscle 
from HSALR mice compared with controls (Supple-
mental Figure 6A), whereas this parameter was 
strongly increased in extensor digitorum longus 
(EDL) mutant muscle (Figure 6A). Since AMPK 
activation by metformin has recently been shown 
to correct mis-splicing in human DM1 cells in vitro 
(38), 4- and 12-month-old control and HSALR mice 
were treated with metformin for 10 days. Despite 
using high doses of metformin, we observed only 
a limited and nonreproducible effect of the treat-
ment on AMPK/S6 activation state in these groups 
of mice analyzed under basal nutritive conditions 
(Supplemental Figure 6B). Besides, the treatment 
failed to reduce the late relaxation time of EDL 
muscle in mutant mice (Figure 6B), and it did not 
modify the expression and splicing of genes affect-
ed in DM1, including Clcn1 (encoding CLC-1, chlo-
ride channel protein 1; inclusion of exon 7a) and Atp2a1 (encoding 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1; exclusion of 
exon 22) (Figure 6C and Supplemental Figure 6C).
As we did not detect any effect of metformin on HSALR mus-
cle, we tested whether 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR), an agonist of AMPK, may constitute an 
alternative strategy to target AMPK activation in muscle. Follow-
ing a 7-day treatment with AICAR, control and mutant muscles 
showed a clear reduction in phospho-S6 levels (Figure 6D). We 
further confirmed that AICAR increased phosphorylated levels 
of AMPK and those of its direct target acetyl-CoA carboxylase 
shortly after the last injection (30 minutes), while inhibition of 
the indirect AMPK target S6 was detected only after 2 hours in 
control muscle (Supplemental Figure 6D). Importantly, follow-
ing tetanic stimuli, a strong and significant reduction in the late 
To test the relevance of autophagy changes in DM1, we looked 
for muscle alterations related to autophagy defects in muscle biop-
sies from DM1 patients and in muscle from aged HSALR mice. As 
previously reported (14, 35–37), vacuolated fibers were observed in 
muscle biopsy of 1 DM1 patient, out of the 3 examined (Figure 5D). 
Lysosome accumulation was also detected in affected fibers from 
DM1 muscle (Figure 5D). However, in contrast to biopsies from 
an inclusion body myositis (IBM) patient, there was no accumu-
lation of LC3, ubiquitinated proteins, or p62 in DM1 patient mus-
cles (Supplemental Figure 5A). Consistently, LC3 levels detected 
by Western blot were similar in DM1 and control biopsies (Figure 
5A). Interestingly, we observed some intracellular vacuoles in mus-
cle from 12-month-old HSALR mice, as well as accumulation of the 
lysosomal marker LAMP1 near the vacuolar structures and myo-
nuclei (Figure 5E). Secondary antibodies alone did not react with 
Table 1. Changes in muscle cross-sectional area and tetanic forces upon treatments 
in HSALR and control mice
Ctrl HSALR
Vehicle AICAR Vehicle AICAR
CSA EDL (mm2)
2M 1.38 ± 0.02 1.31 ± 0.03 1.65 ± 0.05C 1.62 ± 0.01C
8M 1.52 ± 0.00 1.70 ± 0.2 1.86 ± 0.07 1.70 ± 0.04
12M – – 2.46 ± 0.07 2.32 ± 0.02
Po (mN)
2M 185.20 ± 9.01 255.79 ± 9.09D 197.91 ± 13.96 279.97 ± 17.25E
8M 285.37 ± 33.67 273.71 ± 36.71 288.31 ± 15.15 274.39 ± 12.27
12M – – 260.90 ± 26.53 339.42 ± 24.220.07
sPo (mN/mm2)
2M 134.58 ± 4.84 194.73 ± 2.67D 121.23 ± 12.16 173.60 ± 11.05D
8M 187.58 ± 22.01 168.80 ± 34.37 156.89 ± 11.95 161.94 ± 7.34
12M – – 107.33 ± 13.02 146.46 ± 10.510.06
Vehicle Rapamycin Vehicle Rapamycin
CSA EDL (mm2)
4M 1.69 ± 0.12 1.61 ± 0.07 2.04 ± 0.07B 1.96 ± 0.02B
12M 1.67 ± 0.09 1.50 ± 0.10 1.90 ± 0.06 1.77 ± 0.09
Po (mN)
4M 180.94 ± 26.37 170.07 ± 3.91 193.80 ± 13.01 274.48 ± 16.11B,E
12M 226.14 ± 28.30 245.67 ± 16.07 209.59 ± 30.94 240.28 ± 18.95
sPo (mN/mm2)
4M 114.98 ± 21.53 111.32 ± 8.79 99.41 ± 7.64 144.37 ± 8.32E
12M 137.66 ± 23.49 168.87 ± 20.50 109.78 ± 15.01 137.12 ± 12.41
Vehicle AZD8055 Vehicle AZD8055
CSA EDL (mm2) 1.24 ± 0.42 1.67 ± 0.03 2.09 ± 0.09A 2.06 ± 0.04
Po (mN) 185.19 ± 76.17 241.13 ± 80.46 257.96 ± 28.02 353.06 ± 8.90
sPo (mN/mm2) 190.13 ± 23.13 192.38 ± 6.94 124.30 ± 13.88A 171.96 ± 5.22D
CSA, cross-sectional area; M, month; Po, tetanic muscle force; sPo, specific tetanic muscle 
force. CSA = weight/(1.06 * length * 0.44), where 1.06 corresponds to the density of the muscle 
and 0.44 the correction factor for EDL muscle. AICAR, 2-month-old (n = 3 Ctrl and 4 HSALR), 
8-month-old (Ctrl, n = 3; HSALR, n = 6 Veh and 7 AICAR), 12-month-old (HSALR, n = 4 Veh and 
5 AICAR) mice; rapamycin, 4-month-old (Ctrl, n = 4; HSALR, n = 8 Veh and 10 Rapa), 12-month-
old (Ctrl, n = 3; HSALR, n = 5 Veh and 6 Rapa) mice; AZD8055, 8-month-old (Ctrl, n = 3; HSALR, 
n = 5 Veh and 8 AZD) mice. Values are mean ± SEM. AP < 0.05, BP < 0.01, CP < 0.001 compared 
with control mice with same treatment; DP < 0.05, EP < 0.01, compared with same genotype 
treated with vehicle; 2-way ANOVA with Tukey’s multiple comparisons test correction; for 
12-month-old AICAR-treated mice, unpaired 2-tailed Student’s t test.
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI89616
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 5 7jci.org   Volume 127   Number 2   February 2017
in total twitch (Pt) and tetanic (Po) muscle forces in HSALR mice 
compared with controls (Table 1 and Supplemental Table 1). None-
theless, as cross-sectional area [CSA: mass/(density * length * cor-
rection factor)] of EDL muscle was increased in mutant mice, spe-
cific muscle forces (sPt and sPo), representative of the contractile 
capacity of the myofibers, were reduced in HSALR mice compared 
with control animals (Table 1 and Supplemental Table 1). Upon 
AICAR treatment, we observed that both total and specific forces 
of EDL muscle were increased in 2-month-old HSALR and control 
mice, but not in older mice (Table 1 and Supplemental Table 1). 
Altogether, these results indicate that targeting AMPK activation 
by AICAR improves muscle function in HSALR mice by reducing 
myotonia and potentially increasing muscle force, at least in part, 
through splicing correction.
Rapamycin treatment improves muscle function in HSALR mice. 
Based on the abnormal activation of mTORC1 signaling detected in 
HSALR muscle, we wondered whether indirect mTORC1 inhibition 
was part of the effect of AICAR and whether direct mTORC1 inhibi-
tion would improve muscle function in mutant mice. To this purpose, 
we subjected 4- and 12-month-old mice to rapamycin treatment for 
7 and 10 days, respectively. Rapamycin treatment efficiently inhib-
ited mTORC1 signaling, as shown by reduced phospho-S6 levels 
in muscle from control and HSALR mice (Supplemental Figure 7A). 
Rapamycin did not affect muscle half-relaxation time (Supplemen-
tal Figure 7B), but significantly reduced the late relaxation time of 
EDL muscle from 4- and 12-month-old HSALR mice (Figure 7, A and 
relaxation time of EDL muscle was detected in 2- and 12-month-
old AICAR-treated mutant mice, and myotonia was completely 
abrogated with AICAR in the group of 8-month-old HSALR mice 
(Figure 6, E and F). Normalization of the half-relaxation time 
(i.e., time to reduce the maximal force from 100% to 50%) of 
mutant muscle was also observed upon treatment (Supplemen-
tal Figure 6E). As mis-splicing of the Clcn1 gene is thought to 
be the primary cause of myotonia in DM1 (7, 39–41), we inves-
tigated whether the effect of AICAR was related to changes in 
Clcn1 splicing. By end-point PCR, a significant improvement of 
the misregulated Clcn1 splicing was detected upon AICAR treat-
ment (Figure 6G). We confirmed by quantitative PCR that the 
expression of the mis-spliced Clcn1 transcript (containing exon 
7a) was strongly reduced in muscle from AICAR-treated HSALR 
mice, while overall transcript levels of Clcn1 were unchanged 
compared with those in untreated mutant mice (Figure 6, H and 
I). Furthermore, AICAR led to a slight increase in CLC-1 protein 
levels in mutant muscle (Figure 6, J and K). It is worth noting that 
AICAR did not change splicing of the Atp2a1 and Camk2b genes 
in HSALR muscle (Supplemental Figure 6, F and G). Moreover, we 
did not detect any reduction in transcript levels of Rbm3, encod-
ing RNA-binding protein 3 (Figure 6L), previously suggested to 
mediate the effect of AMPK activation on splicing (38).
Besides its effect on myotonia, we wondered whether AICAR 
treatment would change muscle force in mutant mice. As initially 
reported (5), we detected neither muscle wasting nor reduction 
Figure 7. Rapamycin improves muscle function in 
HSALR mice via splicing-independent mechanisms. 
(A) Rapamycin treatment strongly reduces the time 
to relax of HSALR muscle upon tetanic stimulation, 
compared with muscle from vehicle-treated (Veh) 
mutant mice. (B) Rapamycin (Rapa) treatment 
significantly reduces late relaxation time of muscle 
from 4-month-old (Ctrl, n = 4; HSALR, n = 8 Veh and 
10 Rapa) and 12-month-old (Ctrl, n = 3; HSALR, n = 
5 Veh and 6 Rapa) HSALR mice, as compared with 
age-matched, vehicle-treated mutant mice. (C and 
D) Splicing (C) and overall transcript expression (D) 
of the Clcn1 gene are not modified in muscle from 
rapamycin-treated (Rapa) HSALR mice, compared 
with vehicle-treated (Veh) mutant mice. Values are 
relative to vehicle-treated control mice (n = 3 Ctrl 
and 4 Veh-treated and 5 Rapa-treated HSALR). (E) 
Treatment with AZD8055 for 10 days efficiently 
reduces phosphorylation of mTORC1 target, S6, in 
control (Ctrl) and HSALR muscle, but does not change 
AMPK activation. Samples were run on the same 
gel but were noncontiguous. (F) AZD8055 (AZD) 
does not reduce late relaxation time of EDL mutant 
muscle, compared with vehicle-treated (Veh) 
mutant mice. (n = 3 Ctrl and 5 Veh and 8 AZD HSALR 
mice.) Data represent mean ± SEM. **P < 0.01, ***P 
< 0.001, ****P < 0.0001, 2-way ANOVA with Tukey’s 
multiple comparisons test correction.
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mycin affected neither Clcn1 splicing (Figure 7C) nor the overall 
transcript expression of the gene (Figure 7D) in mutant muscle. 
Consistently, splicing of the Atp2a1 gene was also not restored in 
rapamycin-treated HSALR mice (Supplemental Figure 7C). Togeth-
er, these data suggest that mTORC1 inhibition by rapamycin is 
sufficient to improve muscle function in HSALR mice likely through 
splicing-independent mechanisms.
B). Moreover, we detected a significant increase in total and specific 
muscle forces in young rapamycin-treated mutant mice compared 
with vehicle-treated animals. Forces remained unchanged upon 
treatment in older mice (Table 1 and Supplemental Table 1).
To test whether the effect of rapamycin on muscle function 
relied on splicing improvement, we assessed Clcn1 mis-splicing 
(i.e., exon 7a inclusion) by quantitative PCR. Interestingly, rapa-
Figure 8. AMPK activation by AICAR leads to nuclear foci dispersion in HSALR muscle. (A and B) H&E (A) and NADH (B) stains reveal no major 
change in muscle histopathology and oxidative capacity upon AICAR or rapamycin treatment in HSALR mice. Arrowheads and arrows show internal-
ized nuclei and vacuoles, respectively. Scale bars: 50 μm (A), 200 μm (B). (C) Immunostaining for type IIA (bright red), IIX (dark red), and IIB (green) 
myosin heavy chains (MHC) reveals no significant change in the respective proportion of fiber types in TA mutant muscle upon AICAR (n = 3 Ctrl 
and 4 HSALR) or rapamycin (n = 4) treatment, compared with vehicle-treated HSALR mice (n = 6 Ctrl and 7 HSALR). Scale bar: 200 μm. (D) FISH on TA 
muscle sections with a Cy3-CAG10 DNA probe shows accumulation of nuclear foci in HSA
LR muscle (arrows). The number of stained nuclei is signifi-
cantly decreased upon AICAR treatment (n = 4), but not with rapamycin (Rapa, n = 3), compared with vehicle-treated (Veh) mutant mice. Foci are not 
detected in control (Ctrl) muscle. Scale bar: 50 μm; 2 μm for insets. Data in C and D represent mean ± SEM. *P < 0.05, **P < 0.01, 2-way ANOVA with 
Tukey’s multiple comparisons test correction.
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cle from HSALR and control mice to identify changes in muscle 
contractile properties upon treatment. Few type I fibers were pres-
ent in all the muscles analyzed (data not shown). Mutant muscle 
displayed a switch to slower fibers (i.e., increased and reduced 
proportion of IIA and IIB fibers, respectively) compared with 
control muscle (Figure 8C). However, upon AICAR or rapamycin, 
there was no significant change in the proportion of the different 
fiber types in comparison with vehicle-treated mice (Figure 8C).
Since aggregation of (CUG)n-expanded RNA in nuclear foci is 
a histological hallmark in DM1 diseased muscle, we next wondered 
whether the treatments affected their accumulation in HSALR mus-
cle. To this purpose, we performed FISH using a CAG10 DNA probe 
on TA muscle sections from mutant untreated and treated mice. 
Numerous foci were observed in HSALR muscle, while none were 
detected in control muscle (Figure 8D). Interestingly, the number 
of nuclei showing foci was significantly decreased in muscle from 
AICAR-treated mutant mice, while no change was observed with 
rapamycin (Figure 8D). Moreover, foci appeared more diffuse in 
positive nuclei from mutant muscle upon AICAR treatment, com-
pared with untreated conditions (Figure 8D). Altogether, these 
results indicate that changes in muscle metabolic and contractile 
properties do not account for the beneficial effect of the short 
treatments applied to HSALR mice, while reduced muscle pathol-
ogy upon AICAR-mediated acute AMPK activation likely involves 
nuclear foci dispersion in the mutant muscle.
Discussion
The pathogenic mechanisms underlying DM1 disease are still 
not well understood, and most investigations so far have focused 
on splicing defects caused by mRNA toxicity. In this study, we 
uncovered that in DM1, the AMPK and the mTORC1 pathways are 
deregulated and that the autophagic flux is perturbed in skeletal 
muscle. Most importantly, we established that AICAR and rapa-
mycin, which interfere with AMPK/mTORC1 signaling, amelio-
rate DM1 muscle function (Figure 9).
AMPK signaling and PKB/Akt–mTORC1 signaling are cen-
tral metabolic pathways in muscle cells, and their deregulation 
has been related to muscle alterations and disease (27, 32, 44). 
Since rapamycin has been shown to impact on channel func-
tion (e.g., ryanodine receptor 1, RyR1) via its binding to FKBP12, 
we wondered whether mTORC1 inhibition or the drug itself 
mediated the effect of the treatment on myotonia. Hence, con-
trol and HSALR mice were treated for 10 days with AZD8055, 
an ATP-competitive inhibitor of mTORC1. We confirmed that 
AZD8055 strongly decreased phospho-S6 levels in control and 
mutant muscle, while the activation state of AMPK remained 
unchanged (Figure 7E). In contrast to rapamycin, AZD8055 
had no effect on late relaxation time of mutant muscle (Figure 
7F). Nonetheless, total and specific forces of EDL muscle were 
increased in AZD8055-treated mutant mice, as observed with 
rapamycin (Table 1 and Supplemental Table 1). Together, these 
results indicate that mTORC1 inhibition may ameliorate the 
contractile capacity of muscle in HSALR mice and suggest that 
improvement of muscle relaxation upon rapamycin and AICAR 
treatments may be independent of mTORC1.
AICAR, but not rapamycin, leads to nuclear foci dispersion 
in HSALR muscle. To further understand the beneficial effect of 
AICAR and rapamycin in HSALR mice, we investigated whether the 
treatments improved muscle function by affecting the properties 
of the diseased muscle. First, we did not observe major changes in 
the histopathology of HSALR muscle upon 7-day AICAR or 10-day 
rapamycin treatment, compared with untreated conditions (Fig-
ure 8A). Notably, vacuoles remained present in muscle fibers from 
12-month-old AICAR- or rapamycin-treated HSALR mice (Figure 
8A), indicating that the treatments were not sufficient to reverse 
muscle alterations related to impaired autophagy in aging mice. 
As no myotonia was detected in the slow, soleus muscle of HSALR 
mice and as AICAR and rapamycin were previously shown to alter 
muscle fiber types (42, 43), we tested whether changes in muscle 
function upon treatments were related to modification of muscle 
metabolic and contractile capacities. By reduced nicotinamide 
adenine dinucleotide (NADH) staining, we first observed that the 
overall oxidative property of TA muscle was unchanged in AICAR- 
and rapamycin-treated mutant mice, compared with untreated 
animals (Figure 8B). Immunostaining against type I, IIA/X, and 
IIB myosin heavy chains (MHCs) was then conducted in TA mus-
Figure 9. Scheme depicting the deregulation 
of AMPK/mTORC1 signaling pathways in DM1 
muscle. In healthy muscle, the pathways are 
tightly regulated depending on external and 
internal stimuli (e.g., growth factors, energy, 
nutrients). Upon fasting, mTORC1 is inhibited, 
while AMPK is activated, leading to the induction 
of autophagy. In DM1, skeletal muscle does not 
respond to fasting conditions. Deregulation of 
the AMPK/mTORC1 signaling likely contributes 
to muscle dysfunction: rapamycin, an inhibitor of 
mTORC1, and AICAR, an AMPK agonist, both lead 
to marked reduction of myotonia and normalize 
muscle weakness in DM1 mice. The underlying 
mechanisms include RNA splicing–dependent 
and –independent mechanisms.
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ly used to treat diabetes, clinical evaluation of its effect on muscle 
function in DM1 patients is lacking. In contrast to metformin, we 
found a profound effect of AICAR, a more potent AMPK agonist. 
AICAR led to a strong reduction of myotonia in HSALR mice, which 
correlated with improved splicing of the Clcn1 gene and increased 
protein levels of the channel. While AMPK activation was related to 
repression of the RNA-binding protein Rbm3 in vitro, Rbm3 expres-
sion was unchanged in HSALR muscle upon AICAR treatment. As 
we observed dispersion of the nuclear foci formed by the (CUG)
n-expanded RNA aggregation after AICAR treatment, the effect 
of AMPK activation on splicing may be mediated by its interaction 
with other RNA-binding proteins, such as hnRNP H, which were 
implicated in foci stability in DM1 (50, 51). Hence, one may argue 
that AMPK deregulation likely contributes to pathogenesis in DM1 
muscle by perturbing RNA-binding proteins and thereby accen-
tuating foci stability and mis-splicing events (52–54). Notably, we 
cannot rule out that amelioration of muscle relaxation also relies on 
splicing-independent mechanisms. In particular, changes in sodi-
um- and calcium-activated potassium channels or in Ca2+ homeo-
stasis, which have also been suggested to contribute to myotonia 
in DM1 (55–60), may mediate some of the observed effect. Consis-
tently, AMPK has been shown to modulate chloride and potassium 
channels in several cell types, including cardiomyocytes (61, 62). 
Such mechanisms may also contribute to the beneficial effect of 
rapamycin, as it occurs in the absence of splicing changes. Rapamy-
cin could influence intracellular calcium mobilization by dissociat-
ing FKBPs (FK506-binding protein) from RyR1, thereby modifying 
channel activity (63–65). Although AZD8055-dependent mTORC1 
inhibition did not improve muscle relaxation, further investigations 
are required to rule out the involvement of mTORC1 signaling in 
myotonia reduction, given the complexity of the signaling.
While muscle weakness is observed in DM1 patients, it was 
initially not reported in HSALR mice (5). Consistently, in our 
study, total muscle force was not affected in mutant mice but we 
observed reduced specific strength of EDL muscle in HSALR mice. 
Both specific and total muscle forces were increased upon AICAR, 
rapamycin, and AZD8055 treatments in young mutant mice, 
which may be mediated by mTORC1 inhibition as the signaling 
was shown to modulate Ca2+ homeostasis and excitation-con-
traction coupling in skeletal muscle (66). Myotonia reduction and 
increase in muscle force were not caused by modified metabolic 
and contractile properties of the mutant muscle upon the applied 
short-term treatments. However, one can hypothesize that the 
changes expected upon long-term administration of these drugs 
(i.e., switch toward slower fibers) may further positively affect 
DM1 muscle function.
In conclusion, we identified that deregulation of AMPK/
mTORC1 signaling, together with mild autophagy perturbation, 
contributes to DM1-associated muscle alterations. We showed 
that treatments targeting the AMPK/mTORC1 imbalance are 
beneficial for muscle function, though to varying degrees. Wheth-
er alternative AMPK/mTORC1–targeting compounds, as well as 
changes in the dosage, administration mode, or treatment dura-
tion, may further improve muscle function remains to be inves-
tigated. As the drugs used in our study can target the pathways 
body-wide, they may also be beneficial in other tissues and thus 
may represent new treatment options for DM1.
We found that DM1 muscle shows an altered response to ener-
gy/nutrient-deprived conditions, with impaired AMPK activa-
tion and abnormal activation of mTORC1 signaling. Although 
we have not studied the upstream mechanisms involved in 
this deregulation, mis-splicing–dependent CaMKII deficien-
cy could well account for the limited AMPK activation in DM1 
muscle (21, 23–26). Interestingly, Jones et al. recently reported 
increased GSK3β levels and activity in HSALR muscle (45), which 
may also contribute to the perturbation of AMPK in DM1 mus-
cle (46). In parallel, AMPK constitutes an upstream regulator of 
mTORC1 (47), and its deregulation could thus be responsible 
for abnormal mTORC1 activation in DM1 muscle cells. None-
theless, as we did not detect changes in 4E-BP1 levels or mTOR 
phosphorylation in mutant muscle, evidence that the state of 
mTORC1 is modified in DM1 muscle and not only the activation 
of its downstream axis p70S6K/S6 is missing. Previous reports 
suggested that mTORC1 is inhibited in DM1 human neural and 
muscle cells (14, 17), although results were only obtained in vitro 
and the underlying mechanisms have not been investigated. On 
the basis of the abnormal splicing and protein trafficking of the 
insulin receptor in metabolic tissues in DM1 (15, 16), it has also 
been hypothesized that PKB/Akt–mTORC1 may be less respon-
sive to insulin. However, results regarding the activation state of 
PKB/Akt signaling in DM1 human muscle biopsies or cells are 
conflicting (18, 19). In our experiments, we did not detect chang-
es in PKB/Akt activation or in the expression of Insr in HSALR 
muscle, suggesting that AMPK/mTORC1 deregulation is inde-
pendent of insulin receptor deficiency.
Autophagy as a major catabolic process essential for proteo-
stasis has also been suggested to contribute to muscle alterations 
in DM1 (48). The involvement of autophagy in DM1 was largely 
deduced from the presence of autophagic vesicles and/or accu-
mulation of autophagic markers in DM1 cells, but usually without 
dynamic measurement of the autophagic flux (13, 14, 17, 19, 36, 37, 
49). In our study, we combined several methods to establish that 
mild changes in autophagic markers in muscle from HSALR mice are 
caused by autophagic flux limitation during the degradation steps. 
Further, we showed that even prolonged starvation did not fully 
induce autophagy in mutant muscle. We hypothesize that AMPK- 
and mTORC1-independent mechanisms contribute to autophagy 
perturbation, as rapamycin and metformin were not sufficient to 
normalize the flux in HSALR mice. Although this autophagy deregu-
lation may contribute to muscle atrophy in DM1, it is unlikely to be 
the main pathogenic event, as autophagic features were scarce in 
DM1 muscle biopsies, compared with diseases primarily related to 
autophagy defects, such as vacuolar myopathies.
Importantly, we identified that AMPK/mTORC1 deregulation 
likely contributes to alteration of muscle function in DM1. Myo-
tonia, which is due to membrane hyperexcitability, is thought to 
be caused primarily by mis-splicing and thereby deficiency in the 
CLC-1 (5, 7, 39, 41). In contrast to a recent report studying cultured 
human DM1 cells (38), we did not find any effect of metformin on 
the mis-splicing of DM1-affected genes or on the severe myotonia 
observed in HSALR mice. While we cannot rule out that changes 
in dosage and administration may lead to different results, much 
higher concentrations may be required to efficiently stimulate 
AMPK in rodent muscle tissue. Although metformin is common-
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Histology and immunofluorescence. Muscles were frozen in liquid 
nitrogen–cooled isopentane. Eight-micrometer muscle sections were 
stained with H&E or NADH, and observed with an upright micro-
scope (DMR, Leica). For immunostaining, sections were unfixed or 
fixed with 4% paraformaldehyde (PFA), cold acetone, or methanol; 
for some, microwave antigen retrieval was used. Sections were then 
blocked in PBS, 3% BSA, incubated sequentially with primary and 
appropriate secondary fluorescent antibodies (Invitrogen), mounted 
with Vectashield medium (Vector), and observed with a Leica fluores-
cent microscope.
GFP-LC3 puncta analysis. For GFP-LC3 detection, mice were per-
fused with 4% PFA, and muscles were incubated in 30% sucrose over-
night. Cryosections were washed and mounted. Images were recorded 
using a Leica confocal microscope with ×63 or ×100 objectives. The 
number of GFP-LC3 puncta was counted on the 3D reconstructed 
images with Imaris (version 8.1.2) software. Seven to twelve image 
stacks were quantified for each muscle, and the average number of 
GFP-LC3 puncta per volume unit defined within a single fiber (20.8 
× 20.8 × 6.5 μm3) was used for statistical analyses. All GFP quantifica-
tions were done in a blinded way.
Fluorescence in situ hybridization. FISH was conducted on muscle 
cryosections as previously described by Batra et al. (68), using a Cy3-
CAG10 DNA probe. Nuclear foci were observed with a Leica confocal 
microscope with ×40 and ×100 objectives.
Statistics. Quantitative data are displayed as mean ± SEM of inde-
pendent samples, with n (number of individual experiments) ≥ 3. Sta-
tistical analysis of values was performed using Student’s t test or 2-way 
ANOVA test with Tukey’s multiple comparisons test correction, with a 
0.05 level of confidence accepted for statistical significance.
Study approval. Muscle biopsies from DM1 patients were obtained 
from the Neuromuscular Tissue Bank (Department of Neurosciences, 
University of Padova, Padova, Italy) through the Telethon Network of 
Genetic Biobanks and the EuroBioBank, in accordance with European 
recommendation and Italian legislation on ethics. Control and IBM 
human muscle biopsies were from the Department of Pathology, Uni-
versity Hospital Basel (Basel, Switzerland); their use was approved by 
the Ethical Committee of the University Hospital Basel. Human fibro-
blast cell lines were obtained from the platform for immortalization 
of human cells at the Institut de Myologie (Paris, France). Fibroblasts 
derived from skin biopsies were obtained from the MyoBank-AFM 
bank of tissues for research at the Institut de Myologie, a partner in the 
European Union network EuroBioBank, in accordance with European 
recommendation and French legislation on ethics. All animal studies 
were performed in accordance with the European Union guidelines for 
animal care and approved by the Veterinary Office of the Canton of 
Basel city (application number 2601).
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Methods
Mice. Homozygous mice of the mouse line LR20b carrying about 
250 (CTG) repeats within the HSA transgene (HSALR) were obtained 
from Thornton and colleagues (University of Rochester Medical 
Center, Rochester, New York, USA) (5). Mice of the corresponding 
background strain (FVB/N) were used as control. GFP-LC3 HSALR 
and GFP-LC3 FVB/N mice were obtained by crossing of GFP-LC3–
expressing mice (20) with HSALR or FVB/N mice. Mice were geno-
typed for HSALR transgenes by quantification of ACTA1 levels normal-
ized to endogenous actin (mouse Acta1) in genomic DNA. Mice were 
maintained in a conventional specific-pathogen–free facility with a 
fixed light cycle (23°C, 12-hour dark-light cycle). Mice were inject-
ed i.p. with colchicine (Sigma-Aldrich; 0.4 mg/kg) for 2 days, rapa-
mycin (LC Laboratories) for 1 day (4 mg/kg) or 7 or 10 days (2 mg/
kg), AICAR (Toronto Research Chemicals; 500 mg/kg) for 7 days, or 
AZD8055 (LC Laboratories; 10 mg/kg) for 10 days. Mice were treat-
ed with metformin (Sigma-Aldrich; 300 mg/kg) by gavage for 5 or 10 
days. For starvation experiments, mice were sacrificed after 12 hours 
of food deprivation followed by 4 hours of free access to food (fed), 
or after 24 or 45 hours of food deprivation but free access to water 
(starved). In vitro force measurement of EDL and soleus muscles 
was conducted as previously described (32). Half- and late relaxation 
times were calculated according to Moyer et al. (8).
Human muscle cells and biopsy samples. Muscle biopsies frozen in 
nitrogen-cooled isopentane from 3 DM1 patients, aged 33, 34, and 49 
years, and from an IBM patient were analyzed and compared with 5 con-
trol muscle samples from age-matched individuals showing no clinical 
signs of DM1 and normal muscle histology. MyoD-transduced fibro-
blasts from control individuals and patients were cultured in growth 
medium (DMEM, 10% FBS, 50 μg/ml gentamicin) at 37°C under 5% 
CO2. At confluence, transduction into myoblasts was induced by differ-
entiation medium (DMEM, 50 μg/ml gentamicin, 3 μg/ml doxycycline 
hyclate, 10 μg/ml human recombinant insulin) (67). Myotubes obtained 
after 10 days were incubated for 3 hours in growth medium (refed), PBS 
(starved), or PBS supplemented with chloroquine (100 μM).
Western blotting. Cell pellets and muscles powdered in liquid 
nitrogen were lysed in cold RIPA+ buffer (50 mM Tris-HCl pH 8, 150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1% Tri-
ton X, 10% glycerol, phosphatase and protease inhibitors). Follow-
ing dosage (BCA Protein Assay, Sigma-Aldrich), proteins were sep-
arated on SDS-polyacrylamide gels and transferred to nitrocellulose 
membrane. Blots were blocked in TBS, 3% BSA, 0.1% Tween-20, and 
incubated overnight at 4°C with primary antibodies, then for 2 hours 
with HRP-labeled secondary antibodies. Immunoreactivity was 
detected using the ECL Western blot detection reagent LumiGLO 
(KPL) and exposed to Super RX-N films (Fujifilm). Protein expres-
sion was normalized to α-actinin, α-tubulin, or the total protein of 
the corresponding phosphorylated form. Antibodies used are listed 
in Supplemental Methods.
Polymerase chain reaction. Total RNAs were extracted with the 
RNeasy Mini Kit (Qiagen), reverse transcribed with the SuperScript 
III First-Strand Synthesis System (Invitrogen), and amplified with the 
Power SYBR Green Master Mix (Applied Biosystems) or the Hot Fire-
Pol EvaGreen qPCR Mix (Solis BioDyne). Expression of specific spliced 
or pan transcripts was analyzed by end-point PCR and electrophoresis, 
or by quantitative PCR with Step One software and normalization to 
Actn2 expression. Primers are listed in Supplemental Table 2.
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI89616
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
5 6 2 jci.org   Volume 127   Number 2   February 2017
 1. Machuca-Tzili L, Brook D, Hilton-Jones D. Clin-
ical and molecular aspects of the myotonic dys-
trophies: a review. Muscle Nerve. 2005;32(1):1–18.
 2. Brook JD, et al. Molecular basis of myotonic dys-
trophy: expansion of a trinucleotide (CTG) repeat 
at the 3′ end of a transcript encoding a protein 
kinase family member. Cell. 1992;69(2):385.
 3. Mahadevan M, et al. Myotonic dystrophy 
mutation: an unstable CTG repeat in the 
3′ untranslated region of the gene. Science. 
1992;255(5049):1253–1255.
 4. Lin X, et al. Failure of MBNL1-dependent 
post-natal splicing transitions in myotonic dys-
trophy. Hum Mol Genet. 2006;15(13):2087–2097.
 5. Mankodi A, et al. Myotonic dystrophy in trans-
genic mice expressing an expanded CUG repeat. 
Science. 2000;289(5485):1769–1773.
 6. Philips AV, Timchenko LT, Cooper TA. Dis-
ruption of splicing regulated by a CUG-bind-
ing protein in myotonic dystrophy. Science. 
1998;280(5364):737–741.
 7. Mankodi A, et al. Expanded CUG repeats 
trigger aberrant splicing of ClC-1 chloride 
channel pre-mRNA and hyperexcitability of 
skeletal muscle in myotonic dystrophy. Mol Cell. 
2002;10(1):35–44.
 8. Moyer M, Berger DS, Ladd AN, Van Lunteren E. 
Differential susceptibility of muscles to myotonia 
and force impairment in a mouse model of myo-
tonic dystrophy. Muscle Nerve. 2011;43(6):818–827.
 9. Herrendorff R, et al. Identification of plant-de-
rived alkaloids with therapeutic potential 
for myotonic dystrophy type I. J Biol Chem. 
2016;291(33):17165–17177.
 10. Wheeler TM, et al. Reversal of RNA dominance 
by displacement of protein sequestered on triplet 
repeat RNA. Science. 2009;325(5938):336–339.
 11. Sobczak K, Wheeler TM, Wang W, Thornton CA. 
RNA interference targeting CUG repeats in a 
mouse model of myotonic dystrophy. Mol Ther. 
2013;21(2):380–387.
 12. Vignaud A, et al. Progressive skeletal muscle 
weakness in transgenic mice expressing CTG 
expansions is associated with the activation of 
the ubiquitin-proteasome pathway. Neuromuscul 
Disord. 2010;20(5):319–325.
 13. Bargiela A, Cerro-Herreros E, Fernandez-Costa 
JM, Vilchez JJ, Llamusi B, Artero R. Increased 
autophagy and apoptosis contribute to muscle 
atrophy in a myotonic dystrophy type 1 Drosophi-
la model. Dis Model Mech. 2015;8(7):679–690.
 14. Beffy P, et al. Altered signal transduction path-
ways and induction of autophagy in human myo-
tonic dystrophy type 1 myoblasts. Int J Biochem 
Cell Biol. 2010;42(12):1973–1983.
 15. Savkur RS, Philips AV, Cooper TA. Aberrant reg-
ulation of insulin receptor alternative splicing is 
associated with insulin resistance in myotonic 
dystrophy. Nat Genet. 2001;29(1):40–47.
 16. Llagostera E, et al. Role of myotonic dystrophy 
protein kinase (DMPK) in glucose homeo-
stasis and muscle insulin action. PLoS One. 
2007;2(11):e1134.
 17. Denis JA, et al. mTOR-dependent proliferation 
defect in human ES-derived neural stem cells 
affected by myotonic dystrophy type 1. J Cell Sci. 
2013;126(pt 8):1763–1772.
 18. Li X, Zhang W, Lv H, Wang ZX, Yuan Y. [Activ-
ities of Akt pathway and their correlation with 
pathological changes in myotonic dystrophy]. 
Beijing Da Xue Xue Bao. 2010;42(5):526–529.
 19. Loro E, et al. Normal myogenesis and increased 
apoptosis in myotonic dystrophy type-1 muscle 
cells. Cell Death Differ. 2010;17(8):1315–1324.
 20. Mizushima N, Yamamoto A, Matsui M, Yoshimori 
T, Ohsumi Y. In vivo analysis of autophagy in 
response to nutrient starvation using transgenic 
mice expressing a fluorescent autophagosome 
marker. Mol Biol Cell. 2004;15(3):1101–1111.
 21. Suenaga K, et al. Muscleblind-like 1 knockout 
mice reveal novel splicing defects in the myoton-
ic dystrophy brain. PLoS One. 2012;7(3):e33218.
 22. Du H, et al. Aberrant alternative splicing and 
extracellular matrix gene expression in mouse 
models of myotonic dystrophy. Nat Struct Mol 
Biol. 2010;17(2):187–193.
 23. Nakamori M, et al. Splicing biomarkers of disease 
severity in myotonic dystrophy. Ann Neurol. 
2013;74(6):862–872.
 24. Hart PC, et al. MnSOD upregulation sustains 
the Warburg effect via mitochondrial ROS and 
AMPK-dependent signalling in cancer. Nat Com-
mun. 2015;6:6053.
 25. Lee H, et al. NQO1-induced activation of AMPK 
contributes to cancer cell death by oxygen-glu-
cose deprivation. Sci Rep. 2015;5:7769.
 26. Raney MA, Turcotte LP. Evidence for the involve-
ment of CaMKII and AMPK in Ca2+-dependent 
signaling pathways regulating FA uptake and 
oxidation in contracting rodent muscle. J Appl 
Physiol. 2008;104(5):1366–1373.
 27. Bentzinger CF, et al. Differential response of skel-
etal muscles to mTORC1 signaling during atro-
phy and hypertrophy. Skelet Muscle. 2013;3(1):6.
 28. Bentzinger CF, et al. Skeletal muscle-specific 
ablation of raptor, but not of rictor, causes met-
abolic changes and results in muscle dystrophy. 
Cell Metab. 2008;8(5):411–424.
 29. Kang SA, et al. mTORC1 phosphorylation sites 
encode their sensitivity to starvation and rapa-
mycin. Science. 2013;341(6144):1236566.
 30. Roux PP, et al. RAS/ERK signaling promotes 
site-specific ribosomal protein S6 phosphorylation 
via RSK and stimulates cap-dependent transla-
tion. J Biol Chem. 2007;282(19):14056–14064.
 31. Kim J, Kundu M, Viollet B, Guan KL. AMPK and 
mTOR regulate autophagy through direct phosphor-
ylation of Ulk1. Nat Cell Biol. 2011;13(2):132–141.
 32. Castets P, et al. Sustained activation of mTORC1 
in skeletal muscle inhibits constitutive and 
starvation-induced autophagy and causes 
a severe, late-onset myopathy. Cell Metab. 
2013;17(5):731–744.
 33. Masiero E, et al. Autophagy is required to maintain 
muscle mass. Cell Metab. 2009;10(6):507–515.
 34. Klionsky DJ, et al. Guidelines for the use and 
interpretation of assays for monitoring autopha-
gy. Autophagy. 2012;8(4):445–544.
 35. Ueda H, et al. Decreased expression of myotonic 
dystrophy protein kinase and disorganization of 
sarcoplasmic reticulum in skeletal muscle of myo-
tonic dystrophy. J Neurol Sci. 1999;162(1):38–50.
 36. Swash M, Fox KP. Abnormal intrafusal muscle 
fibres in myotonic dystrophy: a study using 
serial sections. J Neurol Neurosurg Psychiatr. 
1975;38(1):91–99.
 37. Ludatscher RM, Kerner H, Amikam S, Gellei B. 
Myotonia dystrophica with heart involvement: 
an electron microscopic study of skeletal, 
cardiac, and smooth muscle. J Clin Pathol. 
1978;31(11):1057–1064.
 38. Laustriat D, et al. In vitro and in vivo modulation 
of alternative splicing by the biguanide met-
formin. Mol Ther Nucleic Acids. 2015;4:e262.
Network of Genetic Biobanks (grant GTB 12001D to CA), the Uni-
versity of Basel and University Hospital Basel (MS), the University 
of Basel–Stadt and Basel-Landschaft (MAR), the Neuromuscular 
Research Association Basel (MS, PC), the Swiss Foundation for 
Research on Muscle Diseases (MAR, MS), and the Swiss National 
Science Foundation (PC, MS).
Address correspondence to: Perrine Castets, Biozentrum, Uni-
versity of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, 
Switzerland. Phone: 41.61.260.22.25; E-mail: perrine.castets@
unibas.ch. Or to: Michael Sinnreich, Neuromuscular Research 
Group, Departments of Neurology and Biomedicine, University 
of Basel, University Hospital Basel, Klingelbergstrasse 50/70, 
CH-4056 Basel, Switzerland. Phone: 41.61.265.25.25; E-mail: 
michael.sinnreich@unibas.ch.
Acknowledgments
We thank C.A. Thornton for the generous gift of HSALR mice, and 
J. Hench and G. Schweighauser (Institute of Pathology, Universi-
ty of Basel, University Hospital Basel) for their help in preparing 
electron microscopy samples. We are grateful to S. Lin (Biozen-
trum, University of Basel) for his technical expertise on muscle 
force measurement and Imaris software, and to J. Kinter and L. 
Tintignac (Neuromuscular Research Group, University of Basel, 
University Hospital Basel) for their constructive comments on the 
project. We also thank the platform for immortalization of human 
cells from the Institut de Myologie (Paris, France) for providing 
human transduced fibroblasts. MHC antibodies, developed by 
H.M. Blau and S. Schiaffino, were obtained from the Developmen-
tal Studies Hybridoma Bank (University of Iowa, Iowa City, Iowa, 
USA). This work was supported by EuroBioBank and Telethon 
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI89616
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 6 3jci.org   Volume 127   Number 2   February 2017
 39. Wheeler TM, Lueck JD, Swanson MS, Dirksen 
RT, Thornton CA. Correction of ClC-1 splicing 
eliminates chloride channelopathy and myotonia 
in mouse models of myotonic dystrophy. J Clin 
Invest. 2007;117(12):3952–3957.
 40. Lueck JD, et al. Chloride channelopathy in myo-
tonic dystrophy resulting from loss of posttran-
scriptional regulation for CLCN1. Am J Physiol 
Cell Physiol. 2007;292(4):C1291–C1297.
 41. Charlet-BN, Savkur RS, Singh G, Philips AV, 
Grice EA, Cooper TA. Loss of the muscle-specific 
chloride channel in type 1 myotonic dystrophy 
due to misregulated alternative splicing. Mol Cell. 
2002;10(1):45–53.
 42. Pauly M, et al. AMPK activation stimulates 
autophagy and ameliorates muscular dystro-
phy in the mdx mouse diaphragm. Am J Pathol. 
2012;181(2):583–592.
 43. Lee CS, et al. Ligands for FKBP12 increase 
Ca2+ influx and protein synthesis to improve 
skeletal muscle function. J Biol Chem. 
2014;289(37):25556–25570.
 44. Grumati P, et al. Autophagy is defective in col-
lagen VI muscular dystrophies, and its reactiva-
tion rescues myofiber degeneration. Nat Med. 
2010;16(11):1313–1320.
 45. Jones K, et al. GSK3β mediates muscle pathol-
ogy in myotonic dystrophy. J Clin Invest. 
2012;122(12):4461–4472.
 46. Suzuki T, et al. Inhibition of AMPK catabolic 
action by GSK3. Mol Cell. 2013;50(3):407–419.
 47. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular 
energy response to control cell growth and sur-
vival. Cell. 2003;115(5):577–590.
 48. Castets P, Frank S, Sinnreich M, Rüegg MA. “Get 
the balance right”: pathological significance of 
autophagy perturbation in neuromuscular disor-
ders. J Neuromuscul Dis. 2016;3(2):127–155.
 49. Dunne PW, Ma L, Casey DL, Harati Y, Epstein HF. 
Localization of myotonic dystrophy protein kinase 
in skeletal muscle and its alteration with disease. 
Cell Motil Cytoskeleton. 1996;33(1):52–63.
 50. Kim N, et al. AMPKα2 translocates into the nucle-
us and interacts with hnRNP H: implications in 
metformin-mediated glucose uptake. Cell Signal. 
2014;26(9):1800–1806.
 51. Kim DH, Langlois MA, Lee KB, Riggs AD, 
Puymirat J, Rossi JJ. HnRNP H inhibits nuclear 
export of mRNA containing expanded CUG 
repeats and a distal branch point sequence. 
Nucleic Acids Res. 2005;33(12):3866–3874.
 52. Zou T, et al. Polyamines modulate the subcellular 
localization of RNA-binding protein HuR through 
AMP-activated protein kinase-regulated phos-
phorylation and acetylation of importin alpha1. 
Biochem J. 2008;409(2):389–398.
 53. Wang W, et al. AMP-activated kinase reg-
ulates cytoplasmic HuR. Mol Cell Biol. 
2002;22(10):3425–3436.
 54. Finley J. Alteration of splice site selection in 
the LMNA gene and inhibition of progerin pro-
duction via AMPK activation. Med Hypotheses. 
2014;83(5):580–587.
 55. Santoro M, et al. Alternative splicing alterations 
of Ca2+ handling genes are associated with Ca2+ 
signal dysregulation in myotonic dystrophy type 
1 (DM1) and type 2 (DM2) myotubes. Neuropathol 
Appl Neurobiol. 2014;40(4):464–476.
 56. Vihola A, et al. Altered expression and splicing 
of Ca(2+) metabolism genes in myotonic dystro-
phies DM1 and DM2. Neuropathol Appl Neurobiol. 
2013;39(4):390–405.
 57. Kimura T, et al. Alternative splicing of RyR1 alters 
the efficacy of skeletal EC coupling. Cell Calcium. 
2009;45(3):264–274.
 58. Kimura T, et al. Altered mRNA splicing of the 
skeletal muscle ryanodine receptor and sarco-
plasmic/endoplasmic reticulum Ca2+-ATPase 
in myotonic dystrophy type 1. Hum Mol Genet. 
2005;14(15):2189–2200.
 59. Tang ZZ, et al. Muscle weakness in myotonic dys-
trophy associated with misregulated splicing and 
altered gating of Ca(V)1.1 calcium channel. Hum 
Mol Genet. 2012;21(6):1312–1324.
 60. Franke C, Hatt H, Iaizzo PA, Lehmann-Horn 
F. Characteristics of Na+ channels and Cl– con-
ductance in resealed muscle fibre segments 
from patients with myotonic dystrophy. J Physiol 
(Lond). 1990;425:391–405.
 61. Andersen MN, Rasmussen HB. AMPK: a reg-
ulator of ion channels. Commun Integr Biol. 
2012;5(5):480–484.
 62. Sukhodub A, et al. AMP-activated protein kinase 
mediates preconditioning in cardiomyocytes by 
regulating activity and trafficking of sarcolem-
mal ATP-sensitive K(+) channels. J Cell Physiol. 
2007;210(1):224–236.
 63. Kaftan E, Marks AR, Ehrlich BE. Effects of 
rapamycin on ryanodine receptor/Ca(2+)-re-
lease channels from cardiac muscle. Circ Res. 
1996;78(6):990–997.
 64. Avila G, Dirksen RT. Rapamycin and FK506 
reduce skeletal muscle voltage sensor expression 
and function. Cell Calcium. 2005;38(1):35–44.
 65. Brillantes AB, et al. Stabilization of calcium 
release channel (ryanodine receptor) function by 
FK506-binding protein. Cell. 1994;77(4):513–523.
 66. Lopez RJ, et al. Raptor ablation in skeletal muscle 
decreases Cav1.1 expression and affects the func-
tion of the excitation-contraction coupling supra-
molecular complex. Biochem J. 2015;466(1):123–135.
 67. Chaouch S, et al. Immortalized skin fibroblasts 
expressing conditional MyoD as a renewable 
and reliable source of converted human muscle 
cells to assess therapeutic strategies for muscu-
lar dystrophies: validation of an exon-skipping 
approach to restore dystrophin in Duchenne 
muscular dystrophy cells. Hum Gene Ther. 
2009;20(7):784–790.
 68. Batra R, et al. Loss of MBNL leads to disruption 
of developmentally regulated alternative polya-
denylation in RNA-mediated disease. Mol Cell. 
2014;56(2):311–322.
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI89616
